Evidence map›Paper›PMID 36105190›Full record

ArticleFrontiers in pharmacology2022

Development of activated endothelial targeted high-density lipoprotein nanoparticles.

Minzhi Yu, Kristen Hong, Reheman Adili, Ling Mei, Lisha Liu, Hongliang He, Yanhong Guo, Y Eugene Chen, Michael Holinstat, Anna Schwendeman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Minzhi YuDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
Kristen HongDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
Reheman AdiliDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, United States.
Ling MeiDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
Lisha LiuDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
Hongliang HeDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
Yanhong GuoDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States.
Y Eugene ChenDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States.
Michael HolinstatDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, United States.
Anna SchwendemanDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · USBioSurfaces (United States) · USMichigan Medicine · USChina Pharmaceutical University · CN

Funding

INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1985 to 2005
$3.5M
NCATS NIH HHS R21 TR003185NHLBI NIH HHS T32 HL125242NIGMS NIH HHS R35 GM131835NIGMS NIH HHS T32 GM007767
6 · The paper itself

Abstract

Endothelial inflammation is an important pathophysiological driving force in various acute and chronic inflammatory diseases. High-density lipoproteins (HDLs) play critical roles in regulating endothelial functions and resolving endothelial inflammation. In the present study, we developed synthetic HDLs (sHDLs) which actively target inflamed endothelium through conjugating vascular cell adhesion protein 1 (VCAM-1) specific VHPK peptide. The active targeting of VHPK-sHDLs was confirmed

Indexed as

anti-inflammationendotheliumhigh-density lipoproteininflammationVCAM-1

Identifiers

PMID36105190
PMCPMC9464908
OpenAlexW4293663484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.